The $59B Quiet Shift Reshaping How Patients Access Care
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
MannKind: It's Complicated
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
MannKind Corporation (NASDAQ:MNKD) Short Interest Up 29.8% in March
MannKind (NASDAQ:MNKD) Shares Gap Up After Insider Buying Activity
MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
MannKind Announces Settlement of Convertible Senior Notes
MannKind to Participate in Upcoming Investor Conferences
MannKind (NASDAQ:MNKD) Stock Price Down 6.6% on Analyst Downgrade
Why MannKind Stock Tumbled on Thursday
MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics
MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
MoneyShow's Best Investment Ideas For 2026: Part 5
MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know
Stuart Tross Sells 47,006 Shares of MannKind (NASDAQ:MNKD) Stock
MannKind Provides Business Updates and 2026 Growth Drivers
Voya Investment Management LLC Sells 480,182 Shares of MannKind Corporation $MNKD
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?
MannKind Shares FUROSCIX® Business Updates
Michael Castagna Sells 65,804 Shares of MannKind (NASDAQ:MNKD) Stock
Head-To-Head Contrast: MannKind (NASDAQ:MNKD) and Virax Biolabs Group (NASDAQ:VRAX)
MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
Contrasting Silo Pharma (NASDAQ:SILO) & MannKind (NASDAQ:MNKD)
MannKind to Present at the Jefferies Global Healthcare Conference
MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
MannKind: Durable Cash Engine, Optional Catalysts Pending
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes